Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

A multidisciplinary evaluation of barriers to enrolling cancer patients into early phase clinical trials: challenges and patient-centric recommendations.

Babiker HM, Davis L, Larson K, Placencia C, Swensen C, Tenneti P, Lim M, Cañamar R, Curtis J, Castillo E, Mancuso J, Rensvold D, Martinez S, Macias L, Recio-Boiles A, Chandana SR, Mahadevan D.

Expert Opin Investig Drugs. 2019 Jul 22. doi: 10.1080/13543784.2019.1646726. [Epub ahead of print]

PMID:
31327293
2.

Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC).

Babiker HM, Karass M, Recio-Boiles A, Chandana SR, McBride A, Mahadevan D.

Expert Opin Investig Drugs. 2019 Jul;28(7):583-592. doi: 10.1080/13543784.2019.1632289. Epub 2019 Jun 21. Review.

PMID:
31215251
3.

Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma.

Islam S, Paek AL, Hammer M, Rangarajan S, Ruijtenbeek R, Cooke L, Weterings E, Mahadevan D.

Oncotarget. 2018 Nov 13;9(89):35875-35890. doi: 10.18632/oncotarget.26251. eCollection 2018 Nov 13.

4.

Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).

Chandana S, Babiker HM, Mahadevan D.

Expert Opin Investig Drugs. 2019 Feb;28(2):161-177. doi: 10.1080/13543784.2019.1557145. Epub 2018 Dec 16. Review.

PMID:
30539678
5.

A call to arms: Unifying the fight against resistance.

Kaushansky A, Hedstrom L, Goldman A, Singh J, Yang PL, Rathod PK, Cynamon M, Wodarz D, Mahadevan D, Tomaras A, Navia MA, Schiffer CA.

Sci Signal. 2018 Oct 23;11(553). pii: eaav0442. doi: 10.1126/scisignal.aav0442.

PMID:
30352947
6.

A comprehensive review of protein kinase inhibitors for cancer therapy.

Kannaiyan R, Mahadevan D.

Expert Rev Anticancer Ther. 2018 Dec;18(12):1249-1270. doi: 10.1080/14737140.2018.1527688. Epub 2018 Oct 9. Review.

PMID:
30259761
7.

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.

Kelly KR, Friedberg JW, Park SI, McDonagh K, Hayslip J, Persky D, Ruan J, Puvvada S, Rosen P, Iyer SP, Stefanovic A, Bernstein SH, Weitman S, Karnad A, Monohan G, VanderWalde A, Mena R, Schmelz M, Spier C, Groshen S, Venkatakrishnan K, Zhou X, Sheldon-Waniga E, Leonard EJ, Mahadevan D.

Clin Cancer Res. 2018 Dec 15;24(24):6150-6159. doi: 10.1158/1078-0432.CCR-18-0286. Epub 2018 Aug 6.

PMID:
30082475
8.

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study.

Kim ES, Kelly K, Paz-Ares LG, Garrido P, Jalal S, Mahadevan D, Gutierrez M, Provencio M, Schaefer E, Shaheen M, Johnston EL, Turner PK, Kambhampati SRP, Beckmann R, Hossain A, John WJ, Goldman JW.

Clin Cancer Res. 2018 Nov 15;24(22):5543-5551. doi: 10.1158/1078-0432.CCR-18-0651. Epub 2018 Aug 6.

PMID:
30082474
9.

A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.

Carducci M, Shaheen M, Markman B, Hurvitz S, Mahadevan D, Kotasek D, Goodman OB Jr, Rasmussen E, Chow V, Juan G, Friberg GR, Gamelin E, Vogl FD, Desai J.

Invest New Drugs. 2018 Dec;36(6):1060-1071. doi: 10.1007/s10637-018-0625-6. Epub 2018 Jul 7.

10.

Ublituximab for the treatment of CD20 positive B-cell malignancies.

Babiker HM, Glode AE, Cooke LS, Mahadevan D.

Expert Opin Investig Drugs. 2018 Apr;27(4):407-412. doi: 10.1080/13543784.2018.1459560. Epub 2018 Apr 3. Review.

PMID:
29609506
11.

Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study.

Puvvada SD, Guillén-Rodríguez JM, Yan J, Inclán L, Heard K, Rivera XI, Anwer F, Mahadevan D, Schatz JH, Persky DO.

Oncology. 2018;94(5):274-280. doi: 10.1159/000486788. Epub 2018 Feb 22.

12.

Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy.

Islam S, Vick E, Huber B, Morales C, Spier C, Cooke L, Weterings E, Mahadevan D.

Oncotarget. 2017 Nov 1;8(59):100326-100338. doi: 10.18632/oncotarget.22222. eCollection 2017 Nov 21.

13.

Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.

Puvvada SD, Guillen-Rodriguez J, Kumar A, Inclán L, Heard K, Rivera XI, Anwer F, Schatz JH, Mahadevan D, Persky DO.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):58-64. doi: 10.1016/j.clml.2017.09.001. Epub 2017 Sep 19.

PMID:
29056470
14.

Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.

Badruddoja MA, Pazzi M, Sanan A, Schroeder K, Kuzma K, Norton T, Scully T, Mahadevan D, Ahmadi MM.

Cancer Chemother Pharmacol. 2018 Jan;81(1):223. doi: 10.1007/s00280-017-3448-9. No abstract available.

PMID:
29034406
15.

Effect of joint pathology, surface preparation and fixation methods on union frequency after first metatarsophalangeal joint arthrodesis: A systematic review of the English literature.

Korim MT, Mahadevan D, Ghosh A, Mangwani J.

Foot Ankle Surg. 2017 Sep;23(3):189-194. doi: 10.1016/j.fas.2016.05.317. Epub 2016 May 18. Review.

PMID:
28865589
16.

Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.

Badruddoja MA, Pazzi M, Sanan A, Schroeder K, Kuzma K, Norton T, Scully T, Mahadevan D, Ahmadi MM.

Cancer Chemother Pharmacol. 2017 Oct;80(4):715-721. doi: 10.1007/s00280-017-3405-7. Epub 2017 Aug 14. Erratum in: Cancer Chemother Pharmacol. 2018 Jan;81(1):223.

PMID:
28808777
17.

Perceptions of control and unrealistic optimism in early-phase cancer trials.

Jansen LA, Mahadevan D, Appelbaum PS, Klein WMP, Weinstein ND, Mori M, Degnin C, Sulmasy DP.

J Med Ethics. 2018 Feb;44(2):121-127. doi: 10.1136/medethics-2016-103724. Epub 2017 Aug 3.

PMID:
28774957
18.

Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors.

Babiker HM, McBride A, Cooke LS, Mahadevan D.

Expert Opin Investig Drugs. 2017 Sep;26(9):1063-1072. doi: 10.1080/13543784.2017.1360275. Epub 2017 Jul 30. Review.

PMID:
28745064
19.

Variations in Unrealistic Optimism Between Acceptors and Decliners of Early Phase Cancer Trials.

Jansen LA, Mahadevan D, Appelbaum PS, Klein WMP, Weinstein ND, Mori M, Degnin C, Sulmasy DP.

J Empir Res Hum Res Ethics. 2017 Oct;12(4):280-288. doi: 10.1177/1556264617720433. Epub 2017 Jul 21.

20.

Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas.

Islam S, Qi W, Morales C, Cooke L, Spier C, Weterings E, Mahadevan D.

Mol Cancer Ther. 2017 Oct;16(10):2083-2093. doi: 10.1158/1535-7163.MCT-17-0089. Epub 2017 Jun 14.

21.

Academic Cancer Center Phase I Program Development.

Frankel AE, Flaherty KT, Weiner GJ, Chen R, Azad NS, Pishvaian MJ, Thompson JA, Taylor MH, Mahadevan D, Lockhart AC, Vaishampayan UN, Berlin JD, Smith DC, Sarantopoulos J, Riese M, Saleh MN, Ahn C, Frenkel EP.

Oncologist. 2017 Apr;22(4):369-374. doi: 10.1634/theoncologist.2016-0409. Epub 2017 Mar 17.

22.

Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients.

Mahadevan D, Mita M, Richards D, McClay E, Heist RS, Kumar A, Sundararajan S, Naing A.

Cancer Chemother Pharmacol. 2017 Apr;79(4):681-688. doi: 10.1007/s00280-017-3258-0. Epub 2017 Mar 13.

PMID:
28289865
23.

Next generation sequencing identifies 'interactome' signatures in relapsed and refractory metastatic colorectal cancer.

Johnson B, Cooke L, Mahadevan D.

J Gastrointest Oncol. 2017 Feb;8(1):20-31. doi: 10.21037/jgo.2016.09.05.

24.

A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.

Sawas A, Farber CM, Schreeder MT, Khalil MY, Mahadevan D, Deng C, Amengual JE, Nikolinakos PG, Kolesar JM, Kuhn JG, Sportelli P, Miskin HP, O'Connor OA.

Br J Haematol. 2017 Apr;177(2):243-253. doi: 10.1111/bjh.14534. Epub 2017 Feb 21.

25.

Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.

Sharman JP, Farber CM, Mahadevan D, Schreeder MT, Brooks HD, Kolibaba KS, Fanning S, Klein L, Greenwald DR, Sportelli P, Miskin HP, Weiss MS, Burke JM.

Br J Haematol. 2017 Feb;176(3):412-420. doi: 10.1111/bjh.14447. Epub 2016 Dec 16.

26.

The Impact of Unrealistic Optimism on Informed Consent in Early-Phase Oncology Trials.

Jansen LA, Mahadevan D, Appelbaum PS, Klein WMP, Weinstein ND, Mori M, Daffé R, Sulmasy DP.

IRB. 2016 Sep-Oct;38(5):1-7. No abstract available.

PMID:
30146857
27.

Extended plantar limb (modified) chevron osteotomy versus scarf osteotomy for hallux valgus correction: A randomised controlled trial.

Mahadevan D, Lines S, Hepple S, Winson I, Harries W.

Foot Ankle Surg. 2016 Jun;22(2):109-13. doi: 10.1016/j.fas.2015.05.012. Epub 2015 Jun 8.

PMID:
27301730
28.

A Comparison of Two Different High-Volume Image-Guided Injection Procedures for Patients With Chronic Noninsertional Achilles Tendinopathy: A Pragmatic Retrospective Cohort Study.

Wheeler PC, Mahadevan D, Bhatt R, Bhatia M.

J Foot Ankle Surg. 2016 Sep-Oct;55(5):976-9. doi: 10.1053/j.jfas.2016.04.017. Epub 2016 Jun 7.

PMID:
27286927
29.

Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.

Wagner AJ, Agulnik M, Heinrich MC, Mahadevan D, Riedel RF, von Mehren M, Trent J, Demetri GD, Corless CL, Yule M, Lyons JF, Oganesian A, Keer H.

Eur J Cancer. 2016 Jul;61:94-101. doi: 10.1016/j.ejca.2016.03.076. Epub 2016 May 5.

30.

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.

Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, Barnett E, Marine J, Miranda M, Azaryan A, Yu X, Nava-Parada P, Mei J, Kipps TJ.

Haematologica. 2016 Jul;101(7):e295-8. doi: 10.3324/haematol.2015.140806. Epub 2016 May 5. No abstract available.

31.

A novel small molecule inhibitor of the DNA repair protein Ku70/80.

Weterings E, Gallegos AC, Dominick LN, Cooke LS, Bartels TN, Vagner J, Matsunaga TO, Mahadevan D.

DNA Repair (Amst). 2016 Jul;43:98-106. doi: 10.1016/j.dnarep.2016.03.014. Epub 2016 Apr 7.

PMID:
27130816
32.

Comparison of features and outcomes of perforated peptic ulcer between Malaysians and foreigners.

Kugan V, Mahadevan DT, Kandasami P.

Med J Malaysia. 2016 Feb;71(1):12-6.

33.

Programming the immune checkpoint to treat hematologic malignancies.

Vick E, Mahadevan D.

Expert Opin Investig Drugs. 2016 Jul;25(7):755-70. doi: 10.1080/13543784.2016.1175433. Epub 2016 Apr 25. Review.

PMID:
27070269
34.

Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial.

Mahadevan D, Attwal M, Bhatt R, Bhatia M.

Bone Joint J. 2016 Apr;98-B(4):498-503. doi: 10.1302/0301-620X.98B4.36880.

PMID:
27037432
35.

Dispositional optimism and therapeutic expectations in early-phase oncology trials.

Jansen LA, Mahadevan D, Appelbaum PS, Klein WM, Weinstein ND, Mori M, Daffé R, Sulmasy DP.

Cancer. 2016 Apr 15;122(8):1238-46. doi: 10.1002/cncr.29908. Epub 2016 Feb 16.

36.

What factors predict the need for further intervention following corticosteroid injection of Morton's neuroma?

Mahadevan D, Salmasi M, Whybra N, Nanda A, Gaba S, Mangwani J.

Foot Ankle Surg. 2016 Mar;22(1):9-11. doi: 10.1016/j.fas.2015.03.007. Epub 2015 Apr 2.

PMID:
26869493
37.

Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.

Qi W, Morales C, Cooke LS, Johnson B, Somer B, Mahadevan D.

Oncotarget. 2015 Dec 8;6(39):41976-87. doi: 10.18632/oncotarget.5659.

38.

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW.

J Clin Oncol. 2015 Jul 20;33(21):2399-404. doi: 10.1200/JCO.2014.60.6327. Epub 2015 Jun 15.

39.

First metatarsophalangeal joint arthrodesis - Do joint configuration and preparation technique matter?

Mahadevan D, Korim MT, Ghosh A, Allen PE, Bhatia M, Mangwani J.

Foot Ankle Surg. 2015 Jun;21(2):103-7. doi: 10.1016/j.fas.2014.10.002. Epub 2014 Oct 25.

PMID:
25937409
40.

Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.

Zullo KM, Guo Y, Cooke L, Jirau-Serrano X, Mangone M, Scotto L, Amengual JE, Mao Y, Nandakumar R, Cremers S, Duong J, Mahadevan D, O'Connor OA.

Clin Cancer Res. 2015 Sep 15;21(18):4097-109. doi: 10.1158/1078-0432.CCR-15-0033. Epub 2015 Apr 15.

41.

Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes.

Mahadevan D, Sutton GR.

Expert Opin Investig Drugs. 2015 May;24(5):725-33. doi: 10.1517/13543784.2015.1021003. Epub 2015 Feb 27. Review.

PMID:
25724698
42.
43.

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).

Mahadevan D, Theiss N, Morales C, Stejskal AE, Cooke LS, Zhu M, Kurtzman D, Swart R, Ong E, Qi W.

Oncotarget. 2015 Feb 10;6(4):1954-66.

44.

Diagnostic Accuracy of Clinical Tests for Morton's Neuroma Compared With Ultrasonography.

Mahadevan D, Venkatesan M, Bhatt R, Bhatia M.

J Foot Ankle Surg. 2015 Jul-Aug;54(4):549-53.

PMID:
25432459
45.

Novel mutations in a patient with ALK-rearranged lung cancer.

Giri S, Patel JK, Mahadevan D.

N Engl J Med. 2014 Oct 23;371(17):1655-6. doi: 10.1056/NEJMc1410799. No abstract available.

PMID:
25337766
46.

First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors.

Shapiro GI, Kwak E, Dezube BJ, Yule M, Ayrton J, Lyons J, Mahadevan D.

Clin Cancer Res. 2015 Jan 1;21(1):87-97. doi: 10.1158/1078-0432.CCR-14-0979. Epub 2014 Oct 21.

47.

Genetic and cytokine changes associated with symptomatic stages of CLL.

Agarwal A, Cooke L, Riley C, Qi W, Mount D, Mahadevan D.

Leuk Res. 2014 Sep;38(9):1097-101. doi: 10.1016/j.leukres.2014.05.017. Epub 2014 Jun 18.

PMID:
25063525
48.

Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2.

Mahadevan D, Morales C, Cooke LS, Manziello A, Mount DW, Persky DO, Fisher RI, Miller TP, Qi W.

PLoS One. 2014 Jun 3;9(6):e95184. doi: 10.1371/journal.pone.0095184. eCollection 2014.

49.

Monoclonal antibodies as therapeutics in human malignancies.

Pandey M, Mahadevan D.

Future Oncol. 2014 Mar;10(4):609-36. doi: 10.2217/fon.13.197. Review.

PMID:
24754592
50.

Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies.

Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJ, Swart RE, Walker MS, Haluska P, Munster PN, Marshall J, Hamid O, Kurzrock R.

Cancer Chemother Pharmacol. 2014 Mar;73(3):467-73. doi: 10.1007/s00280-013-2372-x. Epub 2014 Jan 4.

PMID:
24390424

Supplemental Content

Loading ...
Support Center